Q2 2025 · 13F-HR
B Group, Inc.holdings as filed
Filed 2025-08-14 · accession 0001420506-25-002005
$129.9M
Reported value
17
Positions
2025-06-30
Period end
The Brief · B Group, Inc. · Q2 2025
AI · grounded in 13F
B Group, Inc. established a new position in ADMA valued at $42.2M. The fund also initiated new stakes in INSM for $15.6M and ZLAB for $14M. Additional new positions include AKRO at $12.4M and LLY at $11.7M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 000899104 | ADMA | ADMA BIOLOGICS INC | $42.2M | 32.5% | 2,317,542 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $15.6M | 12.0% | 155,000 | Common | SOLE |
| 98887Q104 | ZLAB | ZAI LAB LTD | $14.0M | 10.8% | 400,000 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $12.4M | 9.55% | 232,446 | Common | SOLE |
| 532457958 | LLY | ELI LILLY & CO | $11.7M | 9.00% | 15,000 | PUT | SOLE |
| 15117K103 | CLLS | CELLECTIS S A | $5.0M | 3.82% | 3,256,501 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $4.2M | 3.20% | 1,800,556 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $4.0M | 3.08% | 110,000 | Common | SOLE |
| 82657M105 | SGHT | SIGHT SCIENCES INC | $3.8M | 2.96% | 930,000 | Common | SOLE |
| 05153U107 | AURA | AURA BIOSCIENCES INC | $3.6M | 2.76% | 572,576 | Common | SOLE |
| 045396207 | ASMB | ASSEMBLY BIOSCIENCES INC | $3.4M | 2.64% | 189,350 | Common | SOLE |
| 462260100 | IOVA | IOVANCE BIOTHERAPEUTICS INC | $2.6M | 1.99% | 1,500,000 | Common | SOLE |
| 90400D908 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $2.5M | 1.89% | 67,600 | CALL | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $1.5M | 1.17% | 35,000 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $1.5M | 1.13% | 35,000 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $1.2M | 0.92% | 80,000 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $840,750 | 0.65% | 75,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.